Pulmonx Analyst Ratings
Pulmonx Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 76.13% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 08/03/2023 | 66.34% | Piper Sandler | $15 → $17 | Maintains | Overweight |
| 07/11/2023 | 56.56% | Citigroup | $14 → $16 | Maintains | Buy |
| 05/03/2023 | 36.99% | Citigroup | $13 → $14 | Maintains | Buy |
| 05/03/2023 | 46.77% | Piper Sandler | $13 → $15 | Maintains | Overweight |
| 05/03/2023 | 36.99% | Morgan Stanley | $11 → $14 | Maintains | Equal-Weight |
| 04/03/2023 | 27.2% | Citigroup | $12 → $13 | Maintains | Buy |
| 02/27/2023 | 46.77% | Wells Fargo | $10 → $15 | Upgrades | Equal-Weight → Overweight |
| 02/24/2023 | 17.42% | Citigroup | $10 → $12 | Maintains | Buy |
| 02/23/2023 | 95.69% | Canaccord Genuity | $18 → $20 | Maintains | Buy |
| 02/23/2023 | 7.63% | Morgan Stanley | $9.5 → $11 | Maintains | Equal-Weight |
| 01/06/2023 | -7.05% | Morgan Stanley | $14 → $9.5 | Maintains | Equal-Weight |
| 01/03/2023 | -21.72% | B of A Securities | → $8 | Downgrades | Neutral → Underperform |
| 12/12/2022 | -41.29% | Wells Fargo | $13.5 → $6 | Maintains | Equal-Weight |
| 12/12/2022 | -2.15% | Citigroup | $14 → $10 | Upgrades | Neutral → Buy |
| 11/07/2022 | 36.99% | Morgan Stanley | $19 → $14 | Maintains | Equal-Weight |
| 11/04/2022 | 27.2% | Piper Sandler | $25 → $13 | Maintains | Overweight |
| 10/11/2022 | 85.91% | Morgan Stanley | $21 → $19 | Maintains | Equal-Weight |
| 08/04/2022 | 105.48% | Morgan Stanley | $19 → $21 | Maintains | Equal-Weight |
| 08/03/2022 | 144.62% | Piper Sandler | $37 → $25 | Maintains | Overweight |
| 07/18/2022 | 95.69% | Stifel | $32 → $20 | Maintains | Buy |
| 07/15/2022 | 85.91% | Morgan Stanley | $30 → $19 | Maintains | Equal-Weight |
| 07/11/2022 | 85.91% | Citigroup | $23 → $19 | Downgrades | Buy → Neutral |
| 05/17/2022 | 125.05% | Citigroup | $32 → $23 | Maintains | Buy |
| 02/25/2022 | 193.54% | Morgan Stanley | $37 → $30 | Maintains | Equal-Weight |
| 02/24/2022 | 164.19% | Wells Fargo | $55 → $27 | Maintains | Equal-Weight |
| 01/07/2022 | 262.04% | Morgan Stanley | $48 → $37 | Maintains | Equal-Weight |
| 12/08/2021 | 340.31% | Piper Sandler | → $45 | Upgrades | Neutral → Overweight |
| 11/03/2021 | 438.16% | Wells Fargo | $56 → $55 | Maintains | Equal-Weight |
| 08/04/2021 | 418.59% | Canaccord Genuity | $65 → $53 | Maintains | Buy |
| 04/01/2021 | 487.08% | Citigroup | → $60 | Initiates Coverage On | → Buy |
| 03/25/2021 | 389.24% | Piper Sandler | → $50 | Initiates Coverage On | → Neutral |
| 03/10/2021 | 604.5% | B of A Securities | → $72 | Upgrades | Neutral → Buy |
| 03/03/2021 | 536.01% | Canaccord Genuity | $49 → $65 | Maintains | Buy |
| 03/03/2021 | 418.59% | Morgan Stanley | $52 → $53 | Maintains | Equal-Weight |
| 12/15/2020 | 408.81% | Morgan Stanley | $46 → $52 | Maintains | Equal-Weight |
| 11/11/2020 | 350.1% | Morgan Stanley | $44 → $46 | Maintains | Equal-Weight |
| 10/26/2020 | 389.24% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 379.45% | Canaccord Genuity | → $49 | Initiates Coverage On | → Buy |
| 10/26/2020 | 389.24% | Stifel | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 330.53% | Morgan Stanley | → $44 | Initiates Coverage On | → Equal-Weight |
| 10/26/2020 | 350.1% | Wells Fargo | → $46 | Initiates Coverage On | → Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/05/2023 | 76.13% | 克雷格-哈勒姆 | →$18 | 开始承保 | →购买 |
| 08/03/2023 | 66.34% | 派珀·桑德勒 | $15→$17 | 维护 | 超重 |
| 07/11/2023 | 56.56% | 花旗集团 | $14→$16 | 维护 | 买 |
| 05/03/2023 | 36.99% | 花旗集团 | $13→$14 | 维护 | 买 |
| 05/03/2023 | 46.77% | 派珀·桑德勒 | $13→$15 | 维护 | 超重 |
| 05/03/2023 | 36.99% | 摩根士丹利 | $11→$14 | 维护 | 等重 |
| 04/03/2023 | 27.2% | 花旗集团 | $12→$13 | 维护 | 买 |
| 02/27/2023 | 46.77% | 富国银行 | $10→$15 | 升级 | 等重→超重 |
| 02/24/2023 | 17.42% | 花旗集团 | $10→$12 | 维护 | 买 |
| 02/23/2023 | 95.69% | 卡纳科特·格纳奇 | $18→$20 | 维护 | 买 |
| 02/23/2023 | 7.63% | 摩根士丹利 | $9.5→$11 | 维护 | 等重 |
| 01/06/2023 | -7.05% | 摩根士丹利 | $14→$9.5 | 维护 | 等重 |
| 01/03/2023 | -21.72% | B of A证券 | →$8 | 评级下调 | 中性→表现不佳 |
| 2022年12月12日 | -41.29% | 富国银行 | $13.5→$6 | 维护 | 等重 |
| 2022年12月12日 | -2.15% | 花旗集团 | $14→$10 | 升级 | 中性→购买 |
| 11/07/2022 | 36.99% | 摩根士丹利 | $19→$14 | 维护 | 等重 |
| 11/04/2022 | 27.2% | 派珀·桑德勒 | $25→$13 | 维护 | 超重 |
| 2022年10月11日 | 85.91% | 摩根士丹利 | $21→$19 | 维护 | 等重 |
| 08/04/2022 | 105.48% | 摩根士丹利 | $19→$21 | 维护 | 等重 |
| 08/03/2022 | 144.62% | 派珀·桑德勒 | $37→$25 | 维护 | 超重 |
| 07/18/2022 | 95.69% | Stifel | $32→$20 | 维护 | 买 |
| 07/15/2022 | 85.91% | 摩根士丹利 | $30→$19 | 维护 | 等重 |
| 07/11/2022 | 85.91% | 花旗集团 | $23→$19 | 评级下调 | 购买→中性 |
| 2022/05/17 | 125.05% | 花旗集团 | $32→$23 | 维护 | 买 |
| 02/25/2022 | 193.54% | 摩根士丹利 | $37→$30 | 维护 | 等重 |
| 02/24/2022 | 164.19% | 富国银行 | $55→$27 | 维护 | 等重 |
| 01/07/2022 | 262.04% | 摩根士丹利 | $48→$37 | 维护 | 等重 |
| 12/08/2021 | 340.31% | 派珀·桑德勒 | →$45 | 升级 | 中性→超重 |
| 11/03/2021 | 438.16% | 富国银行 | $56→$55 | 维护 | 等重 |
| 08/04/2021 | 418.59% | 卡纳科特·格纳奇 | $65→$53 | 维护 | 买 |
| 04/01/2021 | 487.08% | 花旗集团 | →$60 | 开始承保 | →购买 |
| 03/25/2021 | 389.24% | 派珀·桑德勒 | →$50 | 开始承保 | →中性 |
| 03/10/2021 | 604.5% | B of A证券 | →$72 | 升级 | 中性→购买 |
| 03/03/2021 | 536.01% | 卡纳科特·格纳奇 | $49→$65 | 维护 | 买 |
| 03/03/2021 | 418.59% | 摩根士丹利 | $52→$53 | 维护 | 等重 |
| 12/15/2020 | 408.81% | 摩根士丹利 | $46→$52 | 维护 | 等重 |
| 11/11/2020 | 350.1% | 摩根士丹利 | $44→$46 | 维护 | 等重 |
| 10/26/2020 | 389.24% | B of A证券 | →$50 | 开始承保 | →购买 |
| 10/26/2020 | 379.45% | 卡纳科特·格纳奇 | →$49 | 开始承保 | →购买 |
| 10/26/2020 | 389.24% | Stifel | →$50 | 开始承保 | →购买 |
| 10/26/2020 | 330.53% | 摩根士丹利 | →$44 | 开始承保 | →等重 |
| 10/26/2020 | 350.1% | 富国银行 | →$46 | 开始承保 | →等重 |
What is the target price for Pulmonx (LUNG)?
Pulmonx(肺)的目标价格是多少？
The latest price target for Pulmonx (NASDAQ: LUNG) was reported by Craig-Hallum on September 5, 2023. The analyst firm set a price target for $18.00 expecting LUNG to rise to within 12 months (a possible 76.13% upside). 18 analyst firms have reported ratings in the last year.
Craig-Hallum于2023年9月5日报道了Pulmonx(纳斯达克：LONG)的最新目标价。这家分析公司将目标价定为18.00美元，预计肺脏将在12个月内上涨(可能上涨76.13%)。去年有18家分析公司公布了评级。
What is the most recent analyst rating for Pulmonx (LUNG)?
分析师对Pulmonx(肺)的最新评级是多少？
The latest analyst rating for Pulmonx (NASDAQ: LUNG) was provided by Craig-Hallum, and Pulmonx initiated their buy rating.
Craig-Hallum提供了对Pulmonx(纳斯达克代码：LONG)的最新分析师评级，Pulmonx启动了他们的买入评级。
When is the next analyst rating going to be posted or updated for Pulmonx (LUNG)?
下一次分析师对Pulmonx(肺)的评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pulmonx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pulmonx was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Pulmonx的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Pulmonx的上一次评级是在2023年9月5日提交的，所以你应该预计下一次评级将在2024年9月5日左右的某个时候公布。
Is the Analyst Rating Pulmonx (LUNG) correct?
分析师对肺脏(肺)的评级正确吗？
While ratings are subjective and will change, the latest Pulmonx (LUNG) rating was a initiated with a price target of $0.00 to $18.00. The current price Pulmonx (LUNG) is trading at is $10.22, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的肺(肺)评级是以0.00美元至18.00美元的目标价启动的。目前Pulmonx(肺)的交易价格为10.22美元，在分析师的预测范围内。